Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2026)

Prime Medicine (PRME) has 3 years of Non-Current Deffered Revenue data on file, last reported at $57.8 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 4.75% year-over-year to $57.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.8 million (down 4.75% YoY) and the FY2025 annual result came in at $58.1 million, down 8.05% from the prior year.
• Non-Current Deffered Revenue slipped to $57.8 million in Q1 2026, from $58.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $63.2 million in Q4 2024 to a low of $57.8 million in Q1 2026.
• A 3-year average of $60.2 million and a median of $59.8 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• The widest YoY moves for Non-Current Deffered Revenue: up 4.61% in 2025, down 8.05% in 2025.
• Tracing PRME's Non-Current Deffered Revenue over 3 years: stood at $63.2 million in 2024, then dropped by 8.05% to $58.1 million in 2025, then declined by 0.61% to $57.8 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $57.8 million (Q1 2026), $58.1 million (Q4 2025), and $59.8 million (Q3 2025), per Business Quant data.